Meta-analysisindependent cross-checkabstract checked I-GUT-104 in-depth review

Many IBS patients improve on placebo

The placebo response rate in pharmacological trials in patients with irritable bowel syndrome: a systematic review and meta-analysis.

Overview

Bosman M et al.. Lancet Gastroenterol Hepatol 2021 · PMID 33765447 · DOI 10.1016/S2468-1253(21)00023-6

Across 73 trials, about 27% of IBS patients improved overall on dummy pills.

Does the study support the specific claim? No · Methodological quality: high

Study explained simply

What did the researchers want to find out?: Measure the placebo response in IBS trials.
How was the study done?: Meta-analysis of placebo arms.
How many people, animals or samples were studied?: 73 randomised drug trials.
What was actually found?: 27% global improvement, 34% pain improvement on placebo.
How large was the observed effect?: 27.3% (24.3-30.9).
What do the results mean in everyday life?: Feeling better after any change does not prove the change caused it.
What are the study's limitations?: Drug trials only; heterogeneous.
What does it say about Elawady's specific claim?: Shows the 85% figure from experience cannot be taken at face value.
Do the results apply to Germany and Europe?: Applies everywhere.
What can explicitly not be concluded from this study?: Cannot tell how much of a diet effect is placebo.

How large is the placebo response in pharmacological IBS trials and what modifies it?

Study design: Meta-analysis – Systematic review and meta-analysis of placebo arms of RCTs of drugs for IBS
Population: Adults with IBS in placebo arms of 73 RCTs
Country: International
Period: 1959 to April 2020
Sample size: 73 RCTs (70 articles)
Inclusion and exclusion criteria: Placebo-controlled drug RCTs with dichotomous response, >=4 weeks

Exposure / intervention: Placebo
Comparator: Not applicable (pooled proportions)
Endpoints: Placebo response: global improvement, abdominal pain, FDA composite
Statistical methods: Random-effects pooling of proportions; meta-regression of moderators

Results: Pooled placebo response 27.3% (24.3-30.9) global improvement; 34.4% (31.2-37.8) abdominal pain; 17.9% (15.2-21.0) FDA endpoint; substantial heterogeneity.
Absolute risks: Placebo response about 1 in 4 to 1 in 3
Authors' conclusion: More than a quarter of IBS patients respond to placebo; trial design affects the size.

Orienting tool: AMSTAR 2
Type of assessment: simplified assessment (abstract only)
Full formal assessment: no
Overall risk of bias: low
Rationale: Well-conducted; heterogeneity limits precision of a single number.

Shows why uncontrolled before-after improvement (as in personal clinical experience) overestimates treatment effects.

Context for the claimed 85% improvement: large non-specific improvement occurs in IBS without active treatment.

Placebo response in diet trials may differ; diet effects are real in RCTs.

Universal.

Undermines uncontrolled success rates as evidence.

Multidimensional assessment
Multidimensional assessment
Authenticity of the source	verified
Methodological quality	high
Risk of bias	low
Precision of results	moderate
Directness	indirect
Reproducibility	replicated
Consistency with the overall evidence	consistent
Regional transferability	high
Adequacy of the interpretation (by the archive)	not applicable

Placebo/nocebo response in diet trials.